Extended Data Fig. 8: Tissue biomarkers in ctDNA(−) patients.
From: ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Kaplan–Meier analyses for ctDNA(−) patients in the atezolizumab (blue) and observation (red) arms for DFS (left column) and OS (right column) in subgroups defined by high levels (dark colours) and low levels (light colours) of immune biomarkers of response to immunotherapy including PD-L1 by IHC, TMB from WES, tGE3 gene expression signature, and subgroups defined by immune biomarkers of resistance to immunotherapy including the pan-TBRS (F-TBRS) gene expression signature and the angiogenesis gene expression signature.
